| | |
nab-PTX plus RAM
|
PTX plus RAM
|
P value
|
|---|
|
N = 113
|
%
|
N = 138
|
%
|
|---|
|
Age
|
Median (range)
|
67 (25–84)
| |
69 (40–85)
| |
0.16
|
|
> 65
|
71
|
62.8
|
96
|
69.6
|
0.261
|
|
Sex
|
Male
|
78
|
69
|
88
|
63.8
|
0.381
|
|
Female
|
35
|
31
|
50
|
36.2
|
0.381
|
|
ECOG PS
|
0
|
85
|
75.2
|
88
|
63.8
|
0.051
|
|
1
|
25
|
22.1
|
43
|
31.2
|
0.109
|
|
> 2
|
3
|
2.7
|
7
|
5.1
|
0.261
|
|
Previous gastrectomy
|
Yes
|
35
|
31
|
41
|
29.7
|
0.828
|
|
No
|
78
|
69
|
97
|
70.3
|
0.828
|
|
Recurrence during adjuvant chemotherapy
|
6
|
5.3
|
8
|
5.8
|
0.867
|
|
Time to progressive disease on first-line therapy
|
< 6 months
|
75
|
66.4
|
78
|
56.5
|
0.112
|
|
> 6 months
|
38
|
33.6
|
60
|
43.5
|
0.112
|
|
HER2
|
Positive
|
13
|
11.5
|
23
|
16.7
|
0.246
|
|
Negative
|
99
|
87.6
|
112
|
81.1
|
0.165
|
|
Unknown
|
1
|
0.9
|
3
|
2.2
|
0.39
|
|
Histology
|
Diffuse
|
69
|
61.1
|
82
|
59.4
|
0.792
|
|
Intestinal
|
43
|
38.1
|
52
|
37.7
|
0.952
|
|
Mix, Missing
|
1
|
0.9
|
4
|
2.9
|
0.254
|
|
Number of metastatic sites
|
0–1
|
60
|
54
|
62
|
44.9
|
0.198
|
|
2
|
33
|
28.3
|
48
|
36.2
|
0.347
|
|
> 3
|
20
|
17.7
|
28
|
18.9
|
0.604
|
|
Metastatic site
|
Liver
|
32
|
28.3
|
46
|
33.3
|
0.393
|
|
Lung
|
18
|
15.9
|
19
|
13.8
|
0.631
|
|
Lymph node
|
54
|
47.8
|
74
|
53.6
|
0.358
|
|
Peritoneum
|
70
|
61.9
|
80
|
58
|
0.523
|
|
Others
|
13
|
11.5
|
26
|
18.8
|
0.11
|
|
Prior therapy
|
Fluoropyrimidine
|
113
|
100
|
138
|
100
|
–
|
|
Platinum
|
107
|
94.7
|
130
|
94.2
|
0.867
|
|
Trastuzumab
|
10
|
8.8
|
21
|
15.2
|
0.127
|
|
Ascites
|
None
|
59
|
52.2
|
75
|
54.3
|
0.736
|
|
Small
|
22
|
19.5
|
20
|
14.5
|
0.293
|
|
Moderate
|
14
|
12.4
|
15
|
10.9
|
0.708
|
|
Massive
|
18
|
15.9
|
28
|
20.3
|
0.374
|
|
None/small
|
81
|
71.7
|
95
|
68.8
|
0.625
|
|
Moderate/massive
|
32
|
28.3
|
43
|
31.2
|
0.625
|
- nab-PTX nanoparticle albumin-bound paclitaxel, RAM ramucirumab, HER2 human epidermal growth factor receptor 2, ECOG PS Eastern Cooperative Oncology Group performance status
